Document Detail

Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.
MedLine Citation:
PMID:  12271367     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To assess factors predicting final visual outcome after displacement of subretinal hemorrhage (SRH) by intravitreally injected tissue plasminogen activator (TPA) and gas in patients suffering from age-related macular degeneration (ARMD). METHODS: We evaluated retrospectively the records of 67 patients (32 men, 35 women, mean age 77.2 years) suffering from SRH caused by ARMD who underwent TPA and gas injection between April 1996 and October 2000. Visual acuity (VA; preoperative, 1 week and 3 months postoperative) was analyzed with respect to duration and dimension of bleeding (diameter and thickness) and patient's age. RESULTS: Mean preoperative VA was 0.063, compared with 0.1 at 3 months after injection. Twenty-nine of 47 patients (76%) had an increase in VA 1 week after treatment but 14 of these eyes worsened slightly during follow-up. Visual outcome 3 months after therapy was negatively correlated to thickness ( P<0.05) and diameter ( P<0.001) of the SRH. In a statistical model of a multiple regression analysis, postoperative VA and the shift of VA could be predicted by preoperative VA and diameter of SRH. Patient's age, duration and thickness of SRH had no prognostic value for postoperative visual outcome. CONCLUSION: After SRH caused by ARMD, the best visual outcome after TPA + gas injection can be expected in patients with preoperative VA of less than 0.1 caused by a small SRH. In the presence of large SRH (diameter >5 mm) an increase in VA after therapy is unlikely.
Stephan D Schulze; Lutz Hesse
Related Documents :
24312317 - The effect of a maturing antiretroviral program on early mortality for patients with ad...
20703177 - Anatomic and visual outcomes in early versus late macula-on primary retinal detachment ...
25116577 - Intracoronary injection of cd34-cells in chronic ischemic heart failure: 7 years follow...
9113577 - Glare disability and contrast sensitivity before and after cataract surgery.
14759457 - Superficial wound dehiscence after median sternotomy: surgical treatment versus seconda...
6432417 - Auranofin and d-penicillamine: a one year comparative study of safety and efficacy in p...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2002-07-24
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  240     ISSN:  0721-832X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-09-24     Completed Date:  2002-12-19     Revised Date:  2008-05-30    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  717-20     Citation Subset:  IM    
Department of Ophthalmology, Philipps University Marburg, Robert Koch Strasse 4, 35033 Marburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Combined Modality Therapy
Fluorocarbons / therapeutic use*
Macular Degeneration / complications*
Middle Aged
Prone Position
Retinal Hemorrhage / drug therapy*,  etiology
Retrospective Studies
Sulfur Hexafluoride / therapeutic use*
Tissue Plasminogen Activator / therapeutic use*
Visual Acuity / physiology*
Vitreous Body / drug effects
Reg. No./Substance:
0/Fluorocarbons; 2551-62-4/Sulfur Hexafluoride; 76-19-7/perflutren; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficiency of a video-autorefractometer used as a screening device for amblyogenic factors.
Next Document:  Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow i...